Float Short %

4.94

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

1.56

EPS Last/This Y

4.22

EPS This/Next Y

6.56

Price

207.12

Target Price

257.39

Analyst Recom

Performance Q

2.08

Relative Volume

1.22

Beta

0.45

Ticker: ASND

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	ASND	195.95	0.53	8.88	6850
2025-11-11	ASND	200.84	0.52	0.20	6819
2025-11-12	ASND	200.09	0.49	0.24	7239
2025-11-13	ASND	206.63	0.47	0.20	8184
2025-11-14	ASND	204.4	0.45	0.27	10073
2025-11-17	ASND	216.63	0.39	1.48	12455
2025-11-18	ASND	217.01	0.44	1.39	13044
2025-11-19	ASND	212.43	0.50	0.27	13886
2025-11-20	ASND	209.35	0.46	1.13	16862
2025-11-21	ASND	210.49	0.47	0.51	17027
2025-11-24	ASND	209	0.44	0.84	15817
2025-11-25	ASND	206.39	0.45	0.71	16025
2025-11-26	ASND	210.1	0.46	2.07	16358
2025-12-01	ASND	211.07	0.47	1.16	16592
2025-12-02	ASND	202.67	0.50	0.45	17123
2025-12-03	ASND	200.52	0.48	0.02	16982
2025-12-04	ASND	208.53	0.46	0.11	17492
2025-12-05	ASND	205.48	0.46	0.14	17579
2025-12-08	ASND	206.12	0.47	0.28	17602
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	ASND	196.01	90.8	416.5	-2.21
2025-11-11	ASND	201.16	90.8	423.6	-2.21
2025-11-12	ASND	200.15	90.8	417.2	-2.21
2025-11-13	ASND	206.50	90.8	424.1	-2.21
2025-11-14	ASND	204.51	93.8	376.0	-3.28
2025-11-17	ASND	216.56	93.8	390.3	-3.28
2025-11-18	ASND	216.92	106.3	378.3	-3.19
2025-11-19	ASND	212.15	106.3	373.3	-3.19
2025-11-20	ASND	209.35	106.3	375.0	-3.19
2025-11-21	ASND	210.16	68.8	378.4	-3.41
2025-11-24	ASND	208.80	68.8	376.0	-3.41
2025-11-25	ASND	206.65	72.9	375.3	-3.38
2025-11-26	ASND	210.09	72.9	380.9	-3.38
2025-12-01	ASND	210.85	72.9	375.9	-3.38
2025-12-02	ASND	202.16	72.9	368.8	-3.38
2025-12-03	ASND	200.50	72.9	375.6	-3.38
2025-12-04	ASND	208.57	72.9	385.7	-3.38
2025-12-05	ASND	205.44	72.9	374.5	-3.38
2025-12-08	ASND	207.12	72.9	-	-3.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	ASND	0.00	-5.52	5.69
2025-11-11	ASND	0.00	-5.52	5.69
2025-11-12	ASND	0.00	-5.52	5.90
2025-11-13	ASND	0.00	-5.52	5.90
2025-11-14	ASND	0.00	-5.52	5.90
2025-11-17	ASND	0.00	-3.91	0
2025-11-18	ASND	0.00	-3.91	5.85
2025-11-19	ASND	0.00	-3.91	5.85
2025-11-20	ASND	0.00	-3.91	5.87
2025-11-21	ASND	0.00	-3.91	5.87
2025-11-24	ASND	0.00	1.61	5.87
2025-11-25	ASND	0.00	1.61	5.87
2025-11-26	ASND	0.00	1.61	4.94
2025-12-01	ASND	0.00	1.82	4.94
2025-12-02	ASND	0.00	1.82	4.94
2025-12-03	ASND	0.00	1.82	4.94
2025-12-04	ASND	0.00	1.82	4.94
2025-12-05	ASND	0.00	1.82	4.94
2025-12-08	ASND	0.00	1.82	4.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.17

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

Institutional Transactions

1.82

Beta

0.45

Average Sales Estimate Current Quarter

246

Average Sales Estimate Next Quarter

282

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

7.2

Max Drawdown 5-Year %

-61.7

Target Price

257.39

P/E

Forward P/E

48.01

PEG

P/S

17.56

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y

-3.38

EPS Next Y. (Est.)

3.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

1.22

Return on Equity vs Sector %

106.9

Return on Equity vs Industry %

121.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.17

EBIT Estimation

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ASND

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y